BioAge Labs, Inc. Common Stock
BIOAStock
$22.16+402.21%52W
Market Cap$1.01B
P/E—
Div yield—
Beta1.93
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)42.79%
Price vs S&P 500 (4W)10.19%
VGM Score63.51
Market Capitalization$1.01B
Earnings Surprise History
Q1 26-0.52est. -0.65
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.15
4.15
4.20
4.20
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BIOABioAge Labs, Inc. Common Stock | D | A | B | $22.16 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Bioage Labs is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases like obesity by targeting the biology of aging. Its pipeline includes NLRP3 inhibitors and APJ agonists designed to address the underlying mechanisms of age-related metabolic dysfunction.